WCLC 2025: Updated efficacy and safety data presented from Ph 2b REZILIENT1 trial of zipalertinib in EGFRm, amivantamab-ref NSCLC patients September 16, 2025
Positive efficacy data announced from Ph 2 trial of THIO-101 & cemiplimab (Libtayo®) in NSCLC patients who had failed two or more SoC therapy regimens September 16, 2025
Tagrisso + chemo demonstrated a median OS of nearly four years in global Ph 3 FLAURA2 trial in EGFR-mutated advanced NSCLC September 10, 2025
FDA grants HERNEXEOS® Breakthrough Therapy Designation in HER2 (ERBB2)m advanced 1L NSCLC September 10, 2025
WCLC 2025: New HERNEXEOS® data demonstrated promising intracranial responses in patients with advanced HER2m NSCLC with brain mets September 9, 2025
WCLC 2025: RYBREVANT® (amivantamab-vmjw) + LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in 1L EGFRm NSCLC September 9, 2025
WCLC 2025: Longer-Term Follow-Up of Patients Showed Improving, Favorable Trend in OS in Ph 3 HARMONi Clinical Trial for Ivonescimab + Chemo in 2L+ EGFRm NSCLC September 9, 2025
WCLC 2025: Interim Ph 2 Data for Pumitamig (BNT327/BMS986545) in Patients with ES-SCLC Shows Encouraging Antitumor Activity September 9, 2025
WCLC 2025: Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with ES SCLC in IDeate-Lung01 Ph 2 Trial September 9, 2025
WCLC 2025: New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive NSCLC Announced September 9, 2025
Olomorasib receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers September 9, 2025
HERNEXEOS® approved in China for previously treated patients with HER2-mutant advanced NSCLC September 3, 2025
FDA granted Breakthrough Therapy Designation and Orphan Drug Designation for D3S-001 for Patients with KRAS G12C-Mutated Cancers September 3, 2025
First Patient Dosed in Expansion Cohorts of Ph 1/2 SOLARA Trial of BH-30643 in Advanced EGFRm NSCLC September 3, 2025
TT125-802 received two Fast Track designations in patients with NSCLC with either EGFR Ex19del or Ex21 L858R substitution mutation or KRAS-G12C mutation September 3, 2025
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib August 26, 2025
First Patient Dosed in Expansion Cohorts of Ph 1/2 SOLARA Trial of BH-30643 in Advanced EGFRm NSCLC August 26, 2025
Enrollment paused in Ph 1/2 OPAL-1 trial of intratumoral KB707 in solid tumors, prioritizing work on inhaled KB707 in NSCLC August 26, 2025
Nature Medicine Publishes Results of Ph 2 Study of Sacituzumab Tirumotecan Plus Tagitanlimab in 1L NSCLC August 26, 2025
